Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DPJ05C
|
|||
| Drug Name |
TFM735
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40] | Preclinical | [1] | |
| Company |
Mochida
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [1] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017 May 5;802:76-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.